Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “outperform” rating restated by research analysts at Sanford C. Bernstein in a report released on Tuesday, StockRatingsNetwork.com reports. They currently have a €61.50 ($79.87) price target on the stock.
A number of other firms have also recently commented on FME. Analysts at M.M. Warburg Investment Research reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Friday. They now have a €61.00 ($79.22) price target on the stock. Separately, analysts at AlphaValue reiterated an “add” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Thursday, May 16th. They now have a €64.60 ($83.90) price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Monday, May 13th. They now have a €55.00 ($71.43) price target on the stock.
Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of “Hold” and a consensus price target of €55.67 ($72.30).
Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.
